TET2 and angioimmunoblastic T-cell lymphoma: Added to this, because of the frequency of TET2 and IDH1/2 mutations in lymphomas developed from a T-follicular helper cell (e.g., AITL, peripheral T-cell lymphoma not otherwise specified) drugs targeting epigenetic alterations were also used in clinical trials.